A robustness-based approach to systems-oriented drug design
The DOI matches its Crossref record; 104 of the 105 references it cites were found in a registry or an index.
Abstract
Many potential drugs that specifically target a particular protein considered to underlie a given disease have been found to be less effective than hoped, or to cause significant side effects. The intrinsic robustness of living systems against various perturbations is a key factor that prevents such compounds from being successful. By studying complex network systems and reformulating control and communication theories that are well established in engineering, a theoretical foundation for a systems-oriented approach to more effectively control the robustness of living systems, particularly at the cellular level, could be developed. Here, I use examples that are based on existing drugs to illustrate the concept of robustness, and then discuss how a greater consideration of the importance of robustness could influence the design of new drugs that will be intended to control complex systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it is commonly the case in complex biochemical networks that while changes in individual parameters have little effect on the behaviour of biochemical pathways—indeed evolution is thought to have selected for robustness to individual parameter changes”
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The Byzantine generals problem
Lamport, L., Shostak, R., & Pease, M. (1982) · ACM Transactions on Programming Languages and Systems · doi:10.1145/357172.357176 · Cited by 6,023 · cited 1×
“Fail-on failure (also known as Byzantine failure) has been a major problem for communication networks, and is considered to be a crucial problem in complex network systems in genera”
BackgroundDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“A further illustrative case is that of imatinib (Gleevec; Novartis), which is considered as a successful example of a drug that targets the protein product of a disease-causative gen”
BackgroundROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Khan, J., Wei, J. S., Ringnér, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C., et al. (2001) · Nature Medicine · doi:10.1038/89044 · Cited by 2,644
Cited by
Items 501–535 of 535
Data integration with biological pathways
van Iersel, M. (2010) · Research Publications (Maastricht University) · doi:10.26481/dis.20101105mi
PEX5L is differentially expressed in the tumors of patients with glioblastoma.Preprint
Mamoor, S. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/k8gbs
Bianconi, F., Baldelli, E., Ludovini, V., Petricoin, E. F., Crinò, L., & Valigi, P. (2016) · BMC Systems Biology · doi:10.1186/s12918-016-0267-2
Abtahi, M., Mohammadi, Z., Hatef, B., Amini, M., khorrami, M., & Aghanoori, M. (2015) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/1876
“This puts fungal diseases somewhere between viral/ bacterial infectious diseases and cancer and autoimmune diseases (Kitano, 2007).”
Strategies for Expanding Access and Improving the Quality of Pharmaceutical Services
Dias-Souza, M. V. (2016) · IGI Global eBooks · doi:10.4018/978-1-5225-1762-7.ch014
Sabnis, A. (2012) · Digital Archive @ GSU · doi:10.57709/3094392
Etcheverry, M., Moulin-Frier, C., Oudeyer, P., & Levin, M. G. (2024) · eLife · doi:10.7554/elife.92683.1.sa3
Cavallo, C., Hoch, M., & Gupta, S. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-0157-5_10
Etcheverry, M., Moulin-Frier, C., Oudeyer, P., & Levin, M. G. (2024) · eLife · doi:10.7554/elife.92683.3.sa0
Etcheverry, M., Moulin-Frier, C., Oudeyer, P., & Levin, M. G. (2025) · eLife · doi:10.7554/elife.92683.4.sa3
Chronotherapeutic Delivery Systems
Chaturvedi, A., Arora, P., & Shukla, R. (2025) · Wiley eBooks · doi:10.1002/9781119769484.ch14
Wrapper Drugs as Therapeutic Editors of Side Effects
Fernández, A. (2010) · Springer eBooks · doi:10.1007/978-3-642-11792-3_12
Fernández, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-16850-0_12
Schilling, M. (2007) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00007383
Falaguera Mata, M. J. (2022) · Repositori digital de la UPF (Universitat Pompeu Fabra)
Badkas, A. (2023) · Open Repository and Bibliography (University of Luxembourg)
Statistical tools for classification, interpretation and prediction of biological data
Senan, O. (2017) · Rovira & Virgili repository
Manosalva, O. A. C. (2018) · Universidad Industrial de Santander
Computational approaches to pleiotropic drug design for intestinal ischemia-reperfusion injury
Hezekiah, O. S., Afolabi, O. A., Ajike, R. A., Oyekunle, O. S., Ezekiel Oladele, O. J. O., & KOMOLAFE, A. I. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100511
ALMARASHDEH, L. (2023) · Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia)
Nakao, A. (2022) · Institutional Repositories DataBase (IRDB)
Selvarajoo, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1954008
“Despite substantial advances in quantitative modelling (18, 19), however, relatively few examples exist in which a computational systems model has directly and prospectively determined a therapeutic intervention that subsequently translated into clinical use.”
Spandana, V., Giridhar, A., & Chandra, Y. P. (2025) · International Journal of Allied Medical Sciences and Clinical Research
SYSTEMS BIOLOGICAL APPROACHES FOR UNDERSTANDING SPORULATION MECHANISMS OF BACILLUS SUBTILIS (本文)
Morohashi, M. (2007) · KeiO Associated Repository of Academic Resources (Keio University)
Computer-Aided Drug Design: Molecular Modelling and Computational Approaches
Chinchole, P. P., & Kurhade, G. H. (2026) · doi:10.70593/978-81-6632-016-3
BindingDB (2020) · UC San Diego · doi:10.7270/q23t9m2k
Dual‐Targeting Strategies for Chronic Inflammation
Bajaj, K., Yadav, A., Zafar, S., Obukhov, A. G., & Baig, M. S. (2026) · Journal of Cellular Biochemistry · doi:10.1002/jcb.70135
“…complementary pathways, dual‐target therapy has the potential to achieve broader and more durable control of chronic inflammation than interventions directed toward a single signaling pathway, particularly in diseases characterized by pathway redundancy and compensatory signaling [12–14, 34, 35].”
InfluentialBai, F., Huang, Z., Luo, J., Qiu, Y., Huang, S., Huang, C., Liu, T., Zhang, H., & Wang, D. (2023) · doi:10.3389/fphar.2023.1164425.s001
Xi, Y., Miao, Y., Zhou, R., Wang, M., Zhang, F., Li, Y., Zhang, Y., Yang, H., & Guo, F. (2022) · doi:10.3389/fphar.2022.826535.s001
Metadata
- Authors
- Kitano, H.
- Affiliations
- Sony Computer Science Laboratories (JP)
- Corresponding author
- Kitano, Hiroaki
- ORCID
- Kitano, Hiroaki
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-02-23
- Volume
- 6
- Issue
- 3
- Pages
- 202-210
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1504533062
- Cited by
- 488
- References
- 105
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 9 · 2023: 6 · 2022: 15 · 2021: 8 · 2020: 18 · 2019: 20 · 2018: 16 · 2017: 25 · 2016: 29 · 2015: 37 · 2014: 30 · 2013: 32 · 2012: 47
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- robustness, biological robustness, complex networks, control theory, communication theory, cellular systems, drug efficacy, adverse drug reactions, systems biology
- MeSH terms
- Animals, Communicable Diseases, Pharmaceutical Preparations, Humans, Models, Theoretical, Neoplasms, Technology, Pharmaceutical, Drug Design, Signal Transduction, Cell Proliferation, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.